EU presents roadmap to phase out animal testing – strengthens SenzaGen’s long-term market potential
Idag, 07:30
On June 1, 2026, the European Commission presented a roadmap to gradually phase out animal testing in chemical safety assessments. The initiative signals a clear shift towards wider use of non-animal testing methods, including in sensitization testing, and is expected over time to drive increased demand for SenzaGen’s tests.
The roadmap includes concrete measures to replace, reduce and refine animal testing across several sectors, including chemicals, medical devices, pharmaceuticals and consumer products – all key markets for SenzaGen.
The plan marks a shift from ambition to practical implementation, with sensitization testing identified as one of two areas where animal testing is to be fully replaced, with potential implementation in the short term, defined as by 2029.
“The EU’s roadmap represents another important step forward for non-animal testing. The prioritization of sensitization testing strengthens our commercial opportunities, particularly as our GARD® test is already established and accepted by regulators,” says Peter Nählstedt, CEO of SenzaGen.
The EU initiative is part of a broader global trend where regulatory authorities are driving the transition to non-animal testing. Over the past year, authorities in both the United States and the United Kingdom have signalled similar directions, contributing to increased harmonisation and potentially accelerating market acceptance of validated alternative methods.
Contacts
Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Tel: +46 46-275 62 00
Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Tel: +46 46-275 62 00
About us
SenzaGen is a fast‑growing company in the field of non‑animal chemical safety testing. Through ground-breaking innovations that better reflect human biology, the company works toward its vision of advancing and protecting human health while replacing the use of animals in testing. With GLP‑certified laboratories in Sweden and Italy, SenzaGen is driving the shift toward safer and more ethically sustainable testing practices. At the center of the offering is the company’s unique GARD® platform, which combines genomics and machine learning to deliver highly reliable decision‑support data for assessing skin and respiratory sensitization. SenzaGen’s strategy combines commercial focus, regulatory progress, and innovation to support long‑term profitable growth. SenzaGen is headquartered in Lund, Sweden, with subsidiaries in Italy and the United States. For more information, visit www.senzagen.com.
SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser.
Attachments
EU presents roadmap to phase out animal testing – strengthens SenzaGen’s long-term market potential
Ämnen i artikeln
EU presents roadmap to phase out animal testing – strengthens SenzaGen’s long-term market potential
Idag, 07:30
On June 1, 2026, the European Commission presented a roadmap to gradually phase out animal testing in chemical safety assessments. The initiative signals a clear shift towards wider use of non-animal testing methods, including in sensitization testing, and is expected over time to drive increased demand for SenzaGen’s tests.
The roadmap includes concrete measures to replace, reduce and refine animal testing across several sectors, including chemicals, medical devices, pharmaceuticals and consumer products – all key markets for SenzaGen.
The plan marks a shift from ambition to practical implementation, with sensitization testing identified as one of two areas where animal testing is to be fully replaced, with potential implementation in the short term, defined as by 2029.
“The EU’s roadmap represents another important step forward for non-animal testing. The prioritization of sensitization testing strengthens our commercial opportunities, particularly as our GARD® test is already established and accepted by regulators,” says Peter Nählstedt, CEO of SenzaGen.
The EU initiative is part of a broader global trend where regulatory authorities are driving the transition to non-animal testing. Over the past year, authorities in both the United States and the United Kingdom have signalled similar directions, contributing to increased harmonisation and potentially accelerating market acceptance of validated alternative methods.
Contacts
Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Tel: +46 46-275 62 00
Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Tel: +46 46-275 62 00
About us
SenzaGen is a fast‑growing company in the field of non‑animal chemical safety testing. Through ground-breaking innovations that better reflect human biology, the company works toward its vision of advancing and protecting human health while replacing the use of animals in testing. With GLP‑certified laboratories in Sweden and Italy, SenzaGen is driving the shift toward safer and more ethically sustainable testing practices. At the center of the offering is the company’s unique GARD® platform, which combines genomics and machine learning to deliver highly reliable decision‑support data for assessing skin and respiratory sensitization. SenzaGen’s strategy combines commercial focus, regulatory progress, and innovation to support long‑term profitable growth. SenzaGen is headquartered in Lund, Sweden, with subsidiaries in Italy and the United States. For more information, visit www.senzagen.com.
SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser.
Attachments
EU presents roadmap to phase out animal testing – strengthens SenzaGen’s long-term market potential
Ämnen i artikeln
Analys
Inflationen
Intrum
Analys
Inflationen
Intrum
Marknadsöversikt
1 DAG %
Senast
1 mån
